Prognostic implications of negative dobutamine stress echocardiography in African Americans compared to Caucasians by Srivastava, Ajay V et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Cardiovascular Ultrasound
Open Access Research
Prognostic implications of negative dobutamine stress 
echocardiography in African Americans compared to Caucasians
Ajay V Srivastava1, Karthik Ananthasubramaniam*1, Salil J Patel1, 
Natesh Lingam1 and Gordon Jacobsen2
Address: 1Heart and Vascular Institute, Henry Ford Hospital, Detroit, USA and 2Department of Biostatistics & Research Epidemiology, Henry Ford 
Hospital, Detroit, USA
Email: Ajay V Srivastava - asrivas1@hfhs.org; Karthik Ananthasubramaniam* - kananth1@hfhs.org; Salil J Patel - patelsalil@gmail.com; 
Natesh Lingam - nlingam1@hfhs.org; Gordon Jacobsen - gjacobs2@hfhs.org
* Corresponding author    
Abstract
Background: African Americans (AA) have higher rates of cardiovascular morbidity and mortality
than Caucasians (CA). Despite its excellent negative predictive value, the influence of race on the
prognostic implications of negative dobutamine echocardiography in predicting major cardiac
problems is largely unknown.
Methods:  We studied 387 AA and 340 CA patients with negative dobutamine stress
echocardiography (NDSE). Kaplan-Meier survival analysis was used to create freedom-from-event
curves for major adverse cardiac events over a 36-month period, and a Cox proportional-hazards
multivariable model to examine the influence of race on cardiac outcomes.
Results: AA patients were younger (69.4 ± 12.6 vs. 74.2 ± 10.7, p < .001), had higher incidence of
diabetes mellitus (37% vs. 29%, p = .01), hypertension (91% vs. 85%, p = .006), left ventricular
hypertrophy (70% vs. 49%, p < .001) and lower incidence of prior coronary artery disease (27% vs.
34%, p = .05) compared to CA patients. Ejection fraction ≥ 50% was comparable (81% vs. 82%, p
= .8). At 3-years, AA patients had a lower freedom from nonfatal myocardial infarction (92% vs.
96%, p = .006) and any cardiac event (cardiac death, myocardial infarction) (91% vs. 95%, p = .005)
compared to CA patients.
Conclusion: This is the first study to demonstrate that AA patients have higher rates of nonfatal
MI and MACE compared to CA patients with a NDSE. These patients require closer follow-up and
aggressive preventive and treatment strategies should be employed to help reduce cardiovascular
morbidity and mortality despite negative ischemic workup.
Background
Cardiovascular disease accounts for significant morbidity
and mortality in the United States [1,2] and is a major
cause of death in all race groups [3,4]. Prior studies have
shown that racial differences exist among the various eth-
nic groups and African Americans (AA) have the highest
cardiac event rates [5-7]. Overall mortality in AA's has
been attributed to racial disparities and other differences
[5-12]. AA patients have a higher incidence of diabetes
mellitus, hypertension, and obesity [13,14], all of which
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are risk factors for cardiovascular mortality, and prior
reports have shown that reduced access to health care and
lower socio-economic status [13] also contribute to worse
outcomes in this group.
Though there is data demonstrating that AA patients have
a lower incidence of obstructive coronary artery disease
(CAD) compared to Caucasian (CA) patients [15], they
still have significant rates of myocardial infarction and
other cardiac events. This has been partially attributed to
a difference in the pathology of coronary arteriosclerosis
in AA's compared to CA's. Prior studies have shown that
AA's have a higher prevalence of traditional cardiovascular
risk factors [13,14], that collectively play a role causing
dysfunction at the microvasculature level, and thereby
contribute to endothelial dysfunction. These factors con-
currently with an unstable plaque may play a role in
higher events rather than the continuing progression of
coronary artery plaque build-up as seen in CA's [16]. This
dissimilarity in pathology between the 2 groups could
have potential implications when interpreting diagnostic
stress tests performed to rule out CAD.
Stress testing primarily aims to identify significant steno-
sis causing blunting of stress-induced flow reserve; myo-
cardial perfusion imaging detects CAD based on regional
heterogeneities in tracer uptake based on flow reserve
abnormalities and stress echocardiography depends on
ischemic wall motion abnormalities to develop. It has
been demonstrated that when compared to CA's, AA's
have lesser significant epicardial CAD in the presence of
abnormal nuclear perfusion scans indicating that other
factors such as endothelial dysfunction may play a role in
these abnormal functional studies [17].
DSE (Dobutamine stress echocardiography) is routinely
used for risk stratification [17,18] carrying an approxi-
mate cardiac event rate of 1.1% to 1.5% per patient/year,
a mortality rate of 0.13% per patient/year. A NDSE is asso-
ciated with a high negative predictive value [19-21],
thereby adding valuable prognostic information. Yet,
there is no reported literature to our knowledge compar-
ing major adverse cardiovascular events during follow-up
between AA and CA patients with a NDSE. Given the
above-mentioned differences in cardiovascular disease
process and testing between the two ethnic groups, it
would be crucial to examine its implications on the prog-
nostic value of a NDSE.
Methods
Study Population
This study was carried out at a large tertiary care center
involving an unselected patient population. Between Jan-
uary 1, 1999, and December 31, 1999, 1000 consecutive
patients who underwent DSE were screened retrospec-
tively. After applying exclusion criteria (Patients with a
positive DSE, younger than 18 years old, pregnant, men-
tally impaired) 756 patients formed the initial study
group. Patients who underwent very early revasculariza-
tion (< 2 months) after the index-NDSE were also
excluded as these are driven by multiple factors including
patient presentation, high clinical suspicion in the setting
of a NDSE. Given very early revascularization following a
NDSE they were excluded to ascertain the natural long-
term outcomes following NDSE. Only the first event data
was used for patients with more than one event. After
excluding patients of other ethnicities, 727 patients with
NDSE formed the final study group. Indications for per-
forming the DSE included chest pain (36.2%), pre-opera-
tive clearance (17.3%), evaluation for shortness of breath
(6.8%), evaluation for CAD (21.9%), and miscellaneous
causes (17.8%). The institutional review board at the
Henry Ford Hospital approved the study. For purposes of
our study, hypertension was defined as office visit docu-
mentation of hypertension history or patient being on
antihypertensive therapy. Diabetes mellitus was assumed
to be present if there was documentation of diabetes mel-
litus in an office note, or the patient was on antihypergly-
cemics (oral anti-diabetics or insulin).
Hypercholesterolemia was present if office notes men-
tioned a history of hyperlipidemia or if the patient was on
an anti-hyperlipidemic medication. Heart failure was
defined as the presence of a history of systolic heart failure
or left ventricular ejection fraction < 50% or documented
history of diastolic heart failure with EF ≥ 50%. CAD was
defined as a history of previous MI/angina or history of
percutaneous intervention or coronary artery bypass graft-
ing.
Dobutamine Stress Echocardiography Protocol
Images were obtained in the parasternal long-axis and
short-axis, apical 4-chamber, 2-chamber, and apical long-
axis at baseline, and after each incremental dose of dob-
utamine. Images were digitally stored at baseline, low,
intermediate, and high doses to facilitate quad screen dis-
play and analysis. Recovery images were also obtained
and stored on videotape. In the case of suboptimal digital
capture quality; a tape review was performed for interpre-
tation. Heart rate, blood pressure, and 12-lead electrocar-
diograms were recorded at baseline and monitored
through each stage. After baseline images, dobutamine
was initiated at a dose of 10 µg/kg/min and increased at 3-
minute intervals to 20, 30, and up to a maximum of 40
µg/kg/min. Per our lab protocol, atropine is injected
(observing standard precautions and contraindications at
0.2 mg dose increments every minute, up to a total dose
of 2 mg) if ≥ 85% age-predicted maximum heart rate or an
absolute heart rate of ≥ 100 had not been reached after a
3-minute infusion of dobutamine at 20 µg/kg/min). The
test was terminated at the completion of the protocol orCardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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with the development of significant ischemic ST-segment
shifts, intolerable symptoms, ventricular tachycardia,
symptomatic hypotension (or systolic blood pressure < 90
mmHg), or severe hypertension (> 220/110 mmHg). A
NDSE was defined as having a normal contractile
response with dobutamine regardless of resting wall-
motion abnormalities. Visual assessment of wall motion
was performed using the following format: normal,
mildly hypokinetic, severely hypokinetic, akinetic, and
dyskinetic. The ASE standard 16-segment model, which
was the recommended model by the ASE at the time of
this study conception, was used for reporting of wall
motion. Analysis was primarily done by visual assessment
of wall motion. Ejection fraction estimation was based on
visual assessment and an ejection fraction ≥ 50% was
defined as normal. The decision to withhold beta-block-
ers and other anti-anginals was left to the discretion of the
referring physician.
Electrocardiograms were designated as ischemic with the
presence of ≥ 1 mm of horizontal or downsloping ST-seg-
ments 80 ms after the J-point, or if there was ≥ 1 mm ST-
segment elevation in leads without significant Q-waves at
baseline. Patients with a positive stress ECG but normal
peak wall motion were considered to have negative DSE
and were part of the study group.
Endpoints and Definitions
Major adverse cardiac events (MACE) assessed individu-
ally and as a composite were nonfatal myocardial infarc-
tion (MI), cardiac death, and revascularization. Patients
were also followed up for softer endpoints such as unsta-
ble angina. The hard MACE composite of nonfatal MI and
cardiac death was also assessed. A follow-up period of 36
months was used when plotting survival curves. MI was
defined by creatine kinase elevation > 2 times the upper
limit of normal, or troponin elevation above the upper
limits of normal for our lab assay in the setting of chest
pain, or other clinical signs/symptoms suggesting cardiac
ischemia. Cardiac death was documented as death related
to MI (ST-elevation MI or non-ST-elevation MI), conges-
tive heart failure, sudden cardiac death or arrhythmias.
Revascularization included any percutaneous interven-
tion or coronary artery bypass grafting. Unstable angina
was defined as an accelerated pattern of chest pain with
increased frequency, longer anginal duration, and
decreased response to medical therapy, occurrence at rest
or new onset chest pain.
Statistical analyses
A descriptive analysis was performed comparing clinical,
demographic, and echocardiography variables between
AA and CA patients. Student's t test for continuous varia-
bles and chi square analysis for categorical variables were
used. Kaplan-Meier analysis was used to create freedom-
from-event survival curves for individual major clinical
outcomes (non-fatal MI, cardiac death, revascularization,
and any cardiac event). The log-rank test was used for
comparing the survival curves between the 2 groups.
The Cox proportional hazards regression modeling was
used to evaluate clinical, demographic, and stress echocar-
diography variables as predictors of hard MACE (cardiac
death/non-fatal MI). Sub- group analysis was performed
excluding those patients who failed to achieve a PMHR of
≥ 85%. The covariates included age, male gender, diabetes
mellitus, hypertension, previous history of CAD/MI/
revascularization, history of heart failure, hypercholester-
olemia, tobacco use, chest pain, b-blocker/ca-channel
blocker, LVH, EF, and PMHR ≥ 85%. From the multivari-
able modeling, adjusted hazard ratios with 95% confi-
dence intervals were calculated along with p-values. All
statistical analysis was performed using the SAS software
(version 9.1.3). P-values less than 0.05 were considered
statistically significant.
Results
Patient demographic and clinical characteristics
The study group with negative DSE comprised 727
patients of whom 387 were AA, and 340 CA. Mean overall
follow-up was 39 ± 18 months. AA patients were younger
(69.4 ± 12.6 years vs. 74.2 ± 10.7 years, p < .001), had
higher rates of diabetes mellitus (37% vs. 29%, p = .01),
and hypertension (91% vs. 85%, p = .006) at baseline
compared to CA patients (Table 1). CA patients were more
likely to have history of CAD (27% vs. 34%, p = 0.05),
hypercholesterolemia (55% vs. 47%, p = 0.03) and prior
coronary artery bypass graft surgery (11% vs. 7%, p = .04)
compared to AA patients.
Dobutamine stress echocardiography characteristics
AA patients were more likely to have a hypertensive
response (17% vs. 4%, p < .001) compared to CA patients
(Table 2) and less likely to achieve a target heart rate (50%
vs. 61%, p = 0.002) despite comparable beta-blocker/cal-
cium-channel blocker usage (49% vs. 48%, p = 0.8). While
both groups had similar rates of preserved systolic func-
tion (ejection fraction ≥ 50%) at baseline (81% vs. 82%, p
= 0.8), AA's had significantly higher rates of echocardio-
graphic left ventricular hypertrophy (defined as M-mode
measured septal and posterior wall end-diastolic thick-
ness ≥ 11 mm: 70% vs. 49%, p < .001).
Three-year cardiac event-free survival analysis
Kaplan-Meier freedom-from-events analysis showed that
AA patients had a lower freedom from nonfatal MI (92%
vs. 96%, p = 0.006), and any cardiac event (cardiac death/
MI) (91% vs. 95%, p = .005) compared to CA patients
(Figures 1 and 2). Freedom from unstable angina also
trended lower in AA patients compared to CA patientsCardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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(86% vs. 89%, p =. 08). There was no significant difference
in the rates of event-free freedom from cardiac death
(97% vs. 98%, p = .7), and revascularization (94% vs.
96%, p = .5) (Figures 3 and 4). At three years, rates of car-
diac death were similar between both the groups (CA –
0.7% [5/727]; AA – 0.9% [7/727]), whereas rates of non-
fatal MI's were higher in AA's (CA – 2% [15/727]; AA – 5%
[37/727]). Patients from both ethnic cohorts were further
analyzed for hard MACE (cardiac death/non-fatal M.I)
based on the presence or absence of beta-blocker therapy
and no differences were observed (Figures 5 and 6).
Multivariable Cox proportional hazards regression 
analysis
Cox regression analysis was used to evaluate the ability of
race to predict the hard MACE presence of cardiac death/
nonfatal-MI after accounting for study covariates (Table
3). AA ethnicity carried a 2.83-fold higher risk for cardiac
death or non-fatal MI compared to CA patients. The other
significant predictor was older age (1.03-fold higher per
year). Sub-group analysis performed in patients with a
NDSE and PMHR ≥ 85% again demonstrated that AA race
still was a significant (3.23-fold higher) predictor of car-
diac death/nonfatal-MI after accounting for similar clini-
cal and stress variables as listed above (Table 4).
Discussion
This is the first study to our knowledge to directly com-
pare long-term MACE between AA and CA patients with a
NDSE in an unselected patient population. Our study
found that AA patients were more likely to suffer from
non-fatal MI and any MACE compared to CA patients,
despite a NDSE. In multivariate analysis, AA's were twice
more likely to suffer from any cardiac event compared to
CA patients after controlling for clinical and echocardio-
graphic variables.
Baseline patient characteristics in our study are consistent
with many prior studies showing that AA's tend to be
younger, with a greater female preponderance, and have
higher rates of diabetes mellitus, hypertension, and left
ventricular hypertrophy, but lower rates of CAD com-
pared to CA counterparts[22,23]. A low comparable car-
diac death rate in both groups is also consistent with prior
Table 1: Patient characteristics
African-American (N = 387) Caucasian (N = 340) p value
Age (years) 69.0 ± 12.6 74.2 ± 10.7 < 0.001*
Male 148/387 (38%) 151/340 (44%) 0.092
Diabetes 143/387 (37%) 97/340 (29%) 0.016*
CAD 104/387 (27%) 114/340 (34%) 0.051
History of CHF 76/387 (20%) 57/340 (17%) 0.317
Hypertension 354/387 (91%) 289/340 (85%) 0.006*
Hypercholesterolemia 183/387 (47%) 188/340 (55%) 0.031*
Tobacco use 80/387 (21%) 103/340 (30%) 0.003*
Prior MI 82/387 (21%) 76/340 (22%) 0.704
Prior PCI 39/387 (10%) 45/340 (13%) 0.184
Prior CABG 28/387 (7%) 39/340 (11%) 0.049*
Chest pain 35/387 (9%) 24/340 (7%) 0.328
B-blocker/CC-blocker 189/387 (49%) 163/340 (48%) 0.809
*Statistically significant; B = beta; CABG = coronary artery bypass grafting; CAD = coronary arterial disease; CC = calcium channel; CHF = chronic 
heart failure; MI = myocardial infarction; PCI = percutaneous coronary intervention
Table 2: Echocardiography variables
African American Caucasian P value
Hypotensive response 99/387 (26%) 129/337 (38%) < 0.001*
SBP ≥ 200 and DBP ≥ 90 12/381 (3%) 2/333 (1%) 0.014*
SBP ≥ 200 or DBP ≥ 90 64/381 (17%) 13/333 (4%) < 0.001*
LVH 271/387 (70%) 168/340 (49%) < .001*
Ischemic ECG Change 16/385 (4%) 17/337 (5%) 0.568
Baseline WMA 86/385 (22%) 89/338 (26%) 0.211
EF ≥ 50% 314/387 (81%) 277/339 (82%) 0.843
PMHR ≤ 85% 192/386 (50%) 132/338 (39%) 0.002*
*Statistically significant; DBP = diastolic blood pressure; ECG = electrocardiogram; EF = ejection fraction; LVH = left ventricular hypertrophy; 
PMHR = predicted maximal heart rate; SBP = systolic blood pressure; WMA = wall motion abnormalitiesCardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
Page 5 of 12
(page number not for citation purposes)
Kaplan- Meier curves for freedom from non-fatal MI compared by patient race in negative DSE patients (log rank p-value =  0.006) Figure 1
Kaplan- Meier curves for freedom from non-fatal MI compared by patient race in negative DSE patients (log 
rank p-value = 0.006). DSE- Dobutamine stress echocardiography, MI-Myocardial Infarction.
Kaplan- Meier curves for freedom from any cardiac event (cardiac death, MI) compared by patient race in negative DSE  patients (log rank p-value = 0.005) Figure 2
Kaplan- Meier curves for freedom from any cardiac event (cardiac death, MI) compared by patient race in neg-
ative DSE patients (log rank p-value = 0.005). DSE- Dobutamine stress echocardiography, MI-Myocardial Infarction.Cardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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Kaplan- Meier curves for freedom from cardiac death compared by patient race in negative DSE patients (log rank p-value =  0.730) Figure 3
Kaplan- Meier curves for freedom from cardiac death compared by patient race in negative DSE patients (log 
rank p-value = 0.730). DSE- Dobutamine stress echocardiography.
Kaplan- Meier curves for freedom from revascularization compared by patient race in negative DSE patients (log rank p-value =  0.578) Figure 4
Kaplan- Meier curves for freedom from revascularization compared by patient race in negative DSE patients 
(log rank p-value = 0.578). DSE- Dobutamine stress echocardiography.Cardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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Kaplan- Meier curves for freedom from cardiac death compared by presence of absence of beta-blocker therapy in the entire  patient cohort post negative DSE (log rank p-value = 0.759) Figure 5
Kaplan- Meier curves for freedom from cardiac death compared by presence of absence of beta-blocker ther-
apy in the entire patient cohort post negative DSE (log rank p-value = 0.759). DSE- Dobutamine stress echocardiog-
raphy.
Kaplan- Meier curves for freedom from non-fatal M.I compared by presence of absence of beta-blocker therapy in the entire  patient cohort post negative DSE (log rank p-value = 0.135) Figure 6
Kaplan- Meier curves for freedom from non-fatal M.I compared by presence of absence of beta-blocker ther-
apy in the entire patient cohort post negative DSE (log rank p-value = 0.135). DSE- Dobutamine stress echocardiog-
raphy.Cardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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literature, demonstrating a low incidence of cardiac death
in patients with a NDSE [24].
Race and dobutamine stress echocardiography
In our study, AA patients had higher incidences of diabe-
tes mellitus and hypertension, and concomitantly higher
rates of left ventricular hypertrophy. Also, despite compa-
rable rates of similar systolic function in both groups and
lower rates of ischemic disease in AA's, these patients had
worse outcomes. This is consistent with prior reports that
cardiovascular mortality in AA's is more likely to result
from hypertension, obesity, and diabetes mellitus, lead-
ing to increased micro-vascular disease and overall mor-
tality rather than from CAD leading to pump failure
[25,26]. Also, prior 2D echocardiography studies focusing
on left ventricular hypertrophy [27] have shown that AA's
are more likely to have more cardiac events despite a pre-
served left ventricular function [22]. While the overall
incidence of cardiac death was low and similar in both
groups (CA: 0.7% [5/727]; AA: 0.9% [7/727]), AA patients
accounted for a significantly higher percentage of nonfatal
MI's (CA: 2% [15/727]; AA: 5% [37/727]) in this study.
What could account for this? It is well known that stress
echocardiographic (exercise or pharmacologic) tech-
niques have greater specificity (with relatively lesser sensi-
tivity) than stress nuclear techniques for epicardial CAD
detection. This is at least partly related to the need for true
Table 3: Risk-adjusted Cox proportional hazards regression analysis for predicting cardiac death/M.I in African-American and 
Caucasian patients with NDSE
Hazard Ratio 95% CL P-value
Race (African-American) 2.878 1.608 – 5.151 <0.001 *
Age in Years 1.031 1.007 – 1.056 0.011 *
Male 1.392 0.816 – 2.375 0.225
Diabetes 1.522 0.900 – 2.576 0.117
CAD/Prior MI/Prior Revascularization 1.537 0.861 – 2.746 0.146
History of CHF 1.098 0.567 – 2.127 0.781
Hypertension 1.002 0.345 – 2.910 0.997
Hypercholesterolemia 1.002 0.587 – 1.710 0.994
Tobacco Use 1.677 0.954 – 2.948 0.072
Chest Pain 1.587 0.739 – 3.407 0.236
B-Blocker/CC-Blocker 1.164 0.674 – 2.010 0.586
LVH 0.756 0.444 – 1.285 0.301
EF in Percent 0.978 0.955 – 1.002 0.071
PMHR ≥ 85% 1.344 0.788 – 2.292 0.278
*Statistically significant; CAD = coronary arterial disease; CHF = chronic heart failure; CL = confidence limits; EF = ejection fraction; LVH = left 
ventricular hypertrophy; MI = myocardial infarction; PMHR = predicted maximal heart rate; NDSE = Negative Dobutamine Stress 
Echocardiography
Table 4: Risk-adjusted Cox proportional hazards regression analysis for predicting cardiac death/M.I in African-American and 
Caucasian patients with PMHR ≥ 85% and NDSE
Hazard Ratio 95% CL P-value
Race (African-American) 3.234 1.579 – 6.622 0.001 *
Age in Years 1.049 1.012 – 1.086 0.009 *
Male 1.294 0.641 – 2.610 0.472
Diabetes 0.916 0.426 – 1.968 0.822
CAD/Prior MI/Prior Revascularization 2.607 1.205 – 5.639 0.015 *
History of CHF 1.101 0.461 – 2.633 0.828
Hypertension 1.059 0.301 – 3.729 0.929
Hypercholesterolemia 0.811 0.393 – 1.674 0.571
Tobacco Use 1.616 0.760 – 3.435 0.213
Chest Pain 2.457 0.991 – 6.088 0.052
B-Blocker/CC-Blocker 1.153 0.572 – 2.326 0.691
LVH 0.590 0.290 – 1.200 0.145
EF in Percent 0.977 0.945 – 1.011 0.182
*Statistically significant; CAD = coronary arterial disease; CHF = chronic heart failure; CL = confidence limits; EF = ejection fraction; LVH = left 
ventricular hypertrophy; MI = myocardial infarction; PMHR = predicted maximal heart rate; NDSE = Negative Dobutamine Stress 
EchocardiographyCardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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ischemia and wall motion abnormalities for CAD detec-
tion by stress echo caused by hemodynamically signifi-
cant stenosis rather than heterogeneity of flow in nuclear
imaging, which may happen even in absence of signifi-
cant CAD. Thus dobutamine stress echocardiography
could underestimate disease in patients with mild to
moderate non-obstructive CAD due to lack of ischemia
and this may be confounded further by chronotropic
incompetence in presence or absence of beta- blockers.
Also test sensitivity can be reduced if patients are tested on
anti-anginal therapy. Higher rates of nonfatal MI and
unstable angina in AA patients in setting of a NDSE could
imply that this group may have underlying active athero-
sclerosis/endothelial dysfunction, which is underappreci-
ated by current dobutamine stress echocardiographic
techniques that rely on wall-motion abnormalities to
detect ischemia. Prior literature has demonstrated that AA
patients have a 33% excess prevalence of hypertension
and a 50% excess prevalence of diabetes [28,29], both of
which are known risk factors for CAD and are associated
with abnormal coronary and microvascular relaxation
[30-34]. It has also been shown that when left ventricular
hypertrophy and chronic hypertension are present
together they seem to be the most important predictors
for abnormal vasomotor reactivity to endothelium
dependent/independent stimulus both in AA's and CA's,
while normotensive patients (both AA and CA) show no
such differences in response to coronary vasomotor stim-
ulation [30-34]. This carries significance as shown in our
study as not only is diabetes mellitus more prevalent in
AA (Table 1), but also it has been shown that diabetics
especially with CAD carry an increased cardiovascular risk
and carry a less benign prognosis despite a NDSE [35]. As
further suggested by Cortigiani et al, this high-risk cohort
of patients should be evaluated by other non-invasive
measures such coronary flow-reserve assessment by tran-
sthoracic stress echocardiography [36] for better risk strat-
ification. Extrapolating on this is the interesting question
of whether assessment of flow reserve abnormalities at
peak dobutamine infusion in AA with NDSE could poten-
tially identify the higher risk subgroup. This needs further
study.
Based on the much higher prevalence of hypertension,
diabetes, abnormal BP response and LVH, AA patients
likely have a greater predilection for acquired coronary
and microvascular dysfunction explaining higher non-
fatal MI and any overall MACE as seen in our study. Exist-
ing echocardiographic stress testing modalities currently
do not have the robustness of identifying sub clinical
atherosclerosis and endothelial dysfunction. Myocardial
perfusion contrast echocardiography holds this promise
but is not routinely still incorporated in clinical practice.
Nuclear stress imaging techniques such as SPECT relative
perfusion analysis and positron emission tomography
with absolute blood flow quantization could identify flow
reserve abnormalities. In clinical practice dobutamine
echocardiography remains robust to exclude major epi-
cardial disease but cannot rule out non-obstructive
atherosclerosis or endothelial dysfunction both of which
can influence cardiac outcomes.
Despite higher rates of non-fatal MI and total MACE the
entire patient group in our study had low cardiac death
rates over 3 years, regardless of race. This likely reflects the
characteristics of our study group where there was high
prevalence of normal EF (EF being a major determinant of
cardiac death). Our group has previously shown that a
normal contractile response in setting of preserved EF is
associated with a low cardiac death rate over a 3 year fol-
low-up period regardless of heart rates achieved with a
NDSE [37].
Race and target heart rate achievement
It could also be argued that under recognition of CAD in
our study group particularly in AA's could explain higher
subsequent event rates. Only 50% of AA's compared to
61% CA patients achieved PMHR ≥ 85%, (p  = .002),
despite comparable high rates of atrioventricular nodal
blocker use at the time of DSE (49% vs. 48%, p non signif-
icant) in our study. Nevertheless our study sub- target
heart rate percentages are comparable to prior studies,
which have been reported in upto 60%, in patients under-
going DSE [38-40]. Sub-group analysis of patients on and
without beta-blocker therapy showed higher overall
MACE despite a NDSE (87% vs. 93%, p = 0.002) but the
event rate was primarily driven by higher rates of unstable
angina (93% vs. 78%, p < 0.001) and re-vascularization
(97% vs. 93%, p = 0.001), whereas rates of cardiac death
(98% vs. 99%, p = .759) and non-fatal M.I (94% vs. 93%,
p = .135) did not differ (Figures 5 and 6). These results
were consistent across both ethnic patient cohorts. This
likely reflects the influence of beta-blockers on potentially
causing under recognition of CAD due to lack of heart rate
response or reduced ischemia detection due to anti
ischemic effect. Thus patients tend to present back with
angina and undergo coronary angiography and revascu-
larization.
One study specifically assessing racial differences in heart
rate and blood pressure response to dobutamine, reported
a 47% incidence of submaximal heart rate response
despite holding beta-blockers prior to DSE [41]. That
study also showed that compared to CA's, AA patients
(primarily male gender) had a higher elevated baseline
blood pressure and hence an increased hypertensive
response, which likely lead to higher, rates of premature
termination of a DSE and accounting for higher rates of
submaximal tests. As shown in Tables 1 and 2, these find-
ings are replicated in our study demonstrating higherCardiovascular Ultrasound 2008, 6:20 http://www.cardiovascularultrasound.com/content/6/1/20
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baseline blood pressures, more LVH and higher DSE
induced blood pressure responses in AA's compared to CA
patients. Pharmacogenetic studies in AA's show a varied
hemodynamic response to some vasodilators, leading to
altered vasoreactivity [42,43]. Further pharmacological
and clinical studies are warranted in this area, specifically
evaluating the response to dobutamine in AA patients and
whether specific beta receptor responsiveness or pharma-
cokinetic differences may mediate such responses.
Given the high rates of submaximal NDSE in our AA
which could potentially influence cardiac event rates, we
performed a sub-group analysis including only AA and CA
patients who achieved a PMHR ≥ 85% from the study
population. Consistent with overall results, as shown in
Table 4, AA ethnicity continued to be the single most
important predictor of any cardiac event carrying a 3.2-
fold risk, with age (1.04-fold higher per year). and history
of CAD (2.6-fold higher) being the other significant pre-
dictors.
Strengths and limitations
The primary strengths of this study are the large number
of AA patients (387/727, 50%), the long-term follow-up
(3 years) and the real world implications of patients being
tested on AV nodal blocking agents. The weaknesses are
those inherent in retrospective analyses, which can
include documentation inaccuracies and incomplete fol-
low-up. Furthermore AA had more co-morbidities than
CA, which can drive outcomes although we attempted to
account for these factors in the multivariate analysis. In
addition, the results of this study cannot be extrapolated
to outcomes of NDSE if patients are tested in absence of
beta-blockers or calcium-channel blockers.
Conclusion
Our study demonstrates that despite a NDSE, AA patients
have a significant higher incidence of nonfatal MI and
overall MACE compared to CA patients at 3 years, and AA
ethnicity carries a greater than 2-fold increased risk for any
cardiac event. Also, our study shows that AA and CA
patients are two very heterogeneous groups, when com-
pared both by cardiovascular risk factors and stress
echocardiography variables. Interesting possibilities of
fundamental racial differences in responsiveness to dob-
utamine is again raised in our study as in prior studies
[41]. This requires further investigations focusing on
pharmacogenetics of response to dobutamine in AA and
CA's. Physicians should be aware that although NDSE
overall is associated with low cardiac event rates, AA's
have higher rates of nonfatal MI and MACE compared to
CA patients. Further, due to the higher prevalence of risk
factors such hypertension and diabetes mellitus in this
ethnic group, these patients should be monitored closely
and aggressive preventive and treatment strategies be
employed to help reduce cardiovascular morbidity and
mortality.
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